Founded in 2017, spun out of HealthTell in 2018, and now based in San Carlos, CA - RubrYc Therapeutics is a discovery-stage biotherapeutics startup currently focused on driving drug discovery beyond the constraints of immunodominance. RubrYc guides discovery of epitope-selective antibodies that specifically recognize subdominant epitopes on classically challenging target molecules. RubrYc scientists explore infinite peptide sequence space with artificial intelligence to enable rationally programmed in vitro selection of uniquely active mAbs. We have used these advantages to discover RTX-002, an anti-PD-1 Agonist mAb for serious autoimmune diseases, and RTX-003, an anti-CD-25 Treg depleting mAb for management of solid tumors.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):